Laboratory of Immunoregulation, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
J Immunol Methods. 2010 Mar 31;354(1-2):40-4. doi: 10.1016/j.jim.2010.01.008. Epub 2010 Jan 28.
Significant hurdles remain to large-scale implementation of medical interventions in the developing world due to the lack of a modern diagnostic infrastructure. This is especially pertinent to the international roll-out of antiretroviral drugs to treat HIV, which ideally includes a CD4 T-cell count to determine eligibility. We designed a novel technique to estimate mature T-cell numbers by calculating the amount of rearranged T-cell receptor beta genes from dried blood spots of HIV-infected individuals in the United States and Uganda. It was observed that the rearranged T-cell receptor beta count correlated well with total lymphocyte counts from both study populations (Baltimore R=0.602, Uganda R=0.497; p<0.001) and the ability for this measurement to determine antiretroviral initiation was similar to total lymphocyte counts, which can be used to determine eligibility in HIV+children. This technique as well as other dried blood spot based technologies could increase the diagnostic and monitoring capabilities in resource-limited settings.
由于缺乏现代化的诊断基础设施,医学干预措施在发展中国家的大规模实施仍然面临重大障碍。这对于在国际上推广抗逆转录病毒药物治疗 HIV 尤其相关,而这种药物的推广理想情况下需要进行 CD4 T 细胞计数以确定用药资格。我们设计了一种新的技术,通过计算来自美国和乌干达 HIV 感染者干血斑中重组 T 细胞受体β基因的数量来估算成熟 T 细胞的数量。结果表明,重组 T 细胞受体β计数与两个研究人群的总淋巴细胞计数(巴尔的摩 R=0.602,乌干达 R=0.497;p<0.001)相关性良好,并且这种测量方法确定抗逆转录病毒药物起始治疗的能力与总淋巴细胞计数相似,而总淋巴细胞计数可用于确定 HIV 阳性儿童的用药资格。这种技术以及其他基于干血斑的技术可以提高资源有限环境中的诊断和监测能力。